echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > The wolf is coming? Rx-360 international pharmaceutical supply chain alliance march into China

    The wolf is coming? Rx-360 international pharmaceutical supply chain alliance march into China

    • Last Update: 2014-07-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Source: US China Pharmaceutical source July 21, 2014 [news event] according to C & en news on July 14, as more and more APIs, excipients and pharmaceutical preparations are produced in China, rx-360 international pharmaceutical supply chain alliance decided to expand to China During the 14th world pharmaceutical raw materials China Exhibition (CPHI China), rx-360 held its second meeting and began to attract Chinese manufacturers to join the association "CPHI China" held in Shanghai on June 26-28 is an industrial chain procurement platform integrating pharmaceutical raw materials, biopharmaceuticals, preparations, pharmaceutical machinery, packaging equipment and materials The exhibition attracted 2540 suppliers from the pharmaceutical industry to participate in the exhibition, providing a good opportunity for rx-360 to contact Chinese manufacturers [drug source analysis] rx-360 international drug supply chain alliance was established in June 2009, which is an international non-profit organization The main purpose of rx-360 is to create a quality monitoring system and a shared audit platform for global drug production and supply, so as to ensure the quality and authenticity of products in the whole supply chain Rx-360 attracts members and observers, including pharmaceutical companies, biotechnology companies, and suppliers of APIs, raw materials, and excipients Members are required to pay a certain amount of membership fee but have the right to vote Observers mainly include government auditing and regulatory agencies, industry associations, trade and standard setting organizations, such as EFCG, generics Association, IPEC, nipte, PDA, etc Observers do not enjoy the right to vote Rx-360 provides members with third-party audit on suppliers of APIs, excipients, raw materials, basic chemicals and packaging Multiple members can request a third-party audit of a product or project at the same time, and can share the results In this way, the audit cost is significantly reduced because it is shared by multiple companies If a pharmaceutical company is not the initial sponsor of the audit, it is allowed to purchase the corresponding audit report after the report is approved and approved by the supplier Even pharmaceutical companies that are not rx-360 members can purchase audit reports under supplier agreements The quality control of APIs is an increasingly concerned problem of regulatory authorities The quality problems of APIs are often caused by the active adulteration driven by economic interests or the negligence of poor quality control In early 2008, heparin, an anticoagulant of Baite medical company in the United States, caused many deaths due to quality problems, as well as hundreds of allergic reactions and other side effects Some of the "active pharmaceutical ingredients" are from Changzhou Kaipu Biochemical Co., Ltd Western pharmaceutical companies take this opportunity to blame some of China's API suppliers There is no doubt that rx-360, as a public welfare organization, can provide an additional monitoring way for the quality control of drugs, which is a commendable good thing for patients, regulators and pharmaceutical factories Of course, pharmaceutical companies are the biggest beneficiaries They can not only save the cost of the audit of pharmaceutical supplies such as APIs and excipients, but also contact more manufacturers in the pharmaceutical supply chain in the short term Communication between pharmaceutical companies has become more transparent and effective, and even to a certain extent, an alliance of attack and defense has been formed against suppliers On the positive side, suppliers can reach more manufacturers by joining rx-360 However, today's market competition for APIs, excipients and intermediates is almost white hot Some companies even obtain orders with almost no profit quotations, which intensifies the "arms race" among peers Therefore, the author believes that rx-360's entry into China will not only improve quality monitoring, but also make life more difficult for medical suppliers Because of this, India has always resisted the rx-360.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.